Higher levels of PD-L1, PD-L2, PD-1, CD80, CD86, CTLA-4, Tim-3, LAG3, and 4-1BB expression were found in Epstein-Barr virus (EBV)-positive stomach adenocarcinoma (STAD) and cytomegalovirus (CMV)-positive colon and rectum adenocarcinoma (COADREAD) tumors compared to virus-negative tumors, providing the rationale for treating virus-positive tumors by anti-PD-1, and anti-CTLA-4 immune therapy. The gene discussed is CTLA4; the disease is gastric adenocarcinoma.